Actemra Linked to Heart Attacks
Actemra (tocilizumab) lawsuits claim that Genentech, a subsidiary of Roche, failed to warn rheumatoid arthritis (RA) patients about Actemra’s side effects, including heart attacks, heart failure and even death. According to Actemra attorneys, Genentech negligently advertised its arthritis drug to patients by claiming it was safer than the competitor medications. Tocilizumab side effects also include lung complications and pancreatitis, which has a 50 percent risk of death. None of these side effects appear on the Actemra warning label.
FREE ACTEMRA LAWSUIT EVALUATION
GET LEGAL HELP NOW
Actemra, the FDA and STAT Report
STAT investigators found that between 2010 and 2016, the FDA received thousands of complaints about adverse reactions to Actemra, including 1,100 patient deaths. The cause of death listed in the majority of these FDA reports were heart disease, lung disease, and stroke.
The STAT report notes that, although the FDA’s job is to monitor the safety of prescription drugs, it doesn’t verify the adverse-event reports that it receives. Experts accuse the FDA of failing to warn the public of a drug’s safety (not just Actemra) after its approval, which highlights its inability to adequately scrutinize medications and not acting promptly when adverse events are reported.
After analyzing over 500,000 side-effect reports on rheumatoid arthritis drugs, STAT found “clear evidence” that the risks of heart attacks, strokes, heart failure, and other conditions were as high or higher for Actemra patients than for patients taking some competing RA drugs. Actemra competitors, such as Humira, Remicade and Enbrel, all carry warnings about the risk of heart failure, heart attacks, and strokes — Actemra does not carry such warnings.
(The FDA in May 2017 expanded the approved use of Actemra (tocilizumab) to treat adults with giant cell arteritis, an inflammation of blood vessels in and around the scalp, making it the first FDA-approved therapy for this condition.)
Actemra Rheumatoid Arthritis (RA) Patients
By way of the Freedom of Information Act, STAT gave examples of two patients who were prescribed Actemra. A doctor reported that a man suffered a fatal brain bleed, two days after receiving intravenous tocilizumab and no other factor than the drug could have explained his death. Secondly, after a 62-year-old German woman suffered a heart attack in 2014, Roche “ assessed fatal myocardial infarction as related to [tocilizumab]”.
Actemra Studies and Research
The American College of Rheumatology in late 2016 published a study that compared Actemra side effects with Enbrel, another common RA drug. The study found that Actemra increased the risk of heart attacks 1.5 times compared to those patients taking Enbrel. (Unlike Actemra, the Enbrel label warns of the risk of causing or aggravating heart disease.)
One year before the FDA approved Actemra for the US market, the Wall Street Journal reported that the RA drug had been linked to the deaths of 15 people in Japan. The report came from a study of 5,000 Actemra users and a spokesperson for Chugai Pharmaceutical-- partially owned by Roche--said that, due to this study, the company couldn’t deny that there may be “a causal relationship” between the deaths and Actemra. The death rate reported in this 2009 study was similar to that reported about Enbrel, according to a pharmaceutical analyst for Morgan Stanley.
Actemra Side EffectsLegal HelpIf you or a loved one has suffered similar damages or injuries, please fill in our form and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on
READ MORE Personal Injury Settlements and Legal News